Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Avantor, Inc. AVTR

Healthcare — Medical Instruments & Supplies
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total buys
8.69
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy 1 1 1 — 2 1 — 2 — — — —
Sell — — — — — — — — — — — —
Insider Ownership
3.04%

Capital & Financial Ratios

Market Cap
10,730.00
Revenue
6,561.10
Net Income
(578.00)
Free Cash Flow
454.70
Net Debt
3,391.00
Current Ratio
1.78
Debt/Equity
0.66
P/E ratio
0.00
P/S ratio
1.60
P/B ratio
1.86
Past 5Y EPS Growth
—
This Y EPS Growth
(9.69%)
Next Y EPS Growth
8.71%
Next 5Y EPS Growth
2.01%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2027 ‡‡‡‡
2026 ‡‡‡‡
2025 ‡‡‡‡
2024 ‡‡‡‡
2023 ‡‡‡
2022 ‡‡‡‡
2021 ‡‡‡‡
2020 ‡‡‡‡
2019 ‡‡‡‡
2018 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 262.90 261.90 365.40 306.80
Receivables 1,150.20 1,034.50 1,074.60 1,138.90
Inventory 828.10 731.50 818.20 828.70
Other 143.70 118.70 193.00 187.80
2,384.90 2,146.60 2,451.20 2,462.20
2023 2024 2025 Q'26
Payables 625.90 662.80 741.70 743.20
ST’ Debt 259.90 821.10 30.80 37.00
Other 544.30 475.00 559.10 555.60
1,480.30 2,007.50 1,378.90 1,382.00
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow — ‡‡‡‡‡ ‡‡‡‡‡
Earnings — ‡‡‡ ‡‡‡
Book Value — ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 1,581.40 1,692.30 — —
—
’25 1,581.40 1,683.40 1,623.80 1,663.60
6,552.20
’24 1,679.80 1,702.80 1,714.40 1,686.60
6,783.60
’23 1,780.30 1,743.90 1,720.20 1,722.80
6,967.20
’22 1,950.40 1,910.50 1,856.50 1,795.00
7,512.40
’21 1,785.60 1,858.60 1,834.30 1,907.60
7,386.10
’20 1,519.00 1,478.70 1,605.00 1,790.90
6,393.60
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 58.70 178.20 — —
—
’25 109.30 154.40 207.40 152.70
623.80
’24 141.60 281.10 244.80 173.30
840.80
’23 219.50 168.20 230.70 251.60
870.00
’22 152.20 227.50 258.30 205.60
843.60
’21 126.90 263.80 261.90 301.00
953.60
’20 253.10 89.20 281.50 306.00
929.80
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 25.20 140.60 — —
—
’25 81.30 124.80 171.70 117.20
495.00
’24 106.90 235.30 204.00 145.80
692.00
’23 191.50 138.10 193.00 201.00
723.60
’22 127.70 191.20 219.30 172.00
710.20
’21 111.80 240.40 229.30 261.00
842.50
’20 240.50 75.70 266.20 285.80
868.20
in millions of $

EPS

Mar Jun Sep Dec Year
’26 0.06 0.06 — —
—
’25 0.09 0.09 (1.04) 0.08
(0.78)
’24 0.09 0.14 0.08 0.73
1.04
’23 0.18 (0.01) 0.16 0.15
0.47
’22 0.28 0.28 0.25 0.21
1.01
’21 0.25 0.24 0.24 0.13
0.85
’20 0.05 0.08 (0.10) 0.06
0.09

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

2.9
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
— — — ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ 17.91 16.63 19.59 10.62 — — —
Low Price
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 41.99 25.25 28.00 23.32 — — —
High Price
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 14,500 14,500 13,500 13,500 — — —
Employees
‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.52 0.48 0.50 0.49 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 7,512.40 6,967.20 6,783.60 6,552.20 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 34.65% 33.93% 33.60% 32.65% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 851.10 410.50 853.90 (441.30) — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 11.33% 5.89% 12.59% (6.74%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 686.50 321.10 711.50 (530.20) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 421.20 415.30 416.70 418.70 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 11.54 10.31 9.98 9.63 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 1.02 0.48 1.05 (0.78) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.30 1.29 1.24 0.92 ‡‡‡‡ — —
Cash Flow/Sh
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.20) (0.22) (0.22) (0.19) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.09 1.07 1.02 0.73 — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 7.46 7.77 8.77 8.18 ‡‡‡‡ — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 650.90 675.60 679.60 680.60 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡ 20.55 47.40 20.07 0.00 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
PE Ratio
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.83 2.21 2.11 1.19 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.84 2.93 2.40 1.40 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.62 2.96 2.67 1.74 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 27.73 28.53 26.18 22.99 — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 843.60 870.00 840.80 623.80 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (133.40) (146.40) (148.80) (128.80) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 710.20 723.60 692.00 495.00 ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 999.10 904.60 139.10 1,072.30 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6,287.50 5,536.60 4,055.80 3,946.30 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5,914.60 5,273.70 3,793.90 3,580.90 — — —
Net Debt
‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4,855.40 5,252.60 5,956.70 5,565.00 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.84% 2.43% 5.67% (4.44%) — — —
ROA
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6.56% 4.13% 6.95% (1.68%) — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 16.46% 6.35% 12.69% (9.20%) — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Avantor, Inc. (AVTR) is navigating a post-COVID hangover in the life sciences supply chain, with revenue sliding from a $7.52 billion peak in 2022 to a projected $6.55 billion low in 2025 amid structural pressures and competition from giants like Thermo Fisher. Profitability swings wildly—EBT soaring to 12.6% margins in 2024 before a forecasted $441 million loss next year—yet gross margins hold steady at 32-34%, and the balance sheet strengthens with debt slashed 43% to $4.05 billion since its 2017 LBO. At dirt-cheap valuations (2.1x PS, 2.4x PB), the stock lags despite resilient FCF, trading near lows with analysts eyeing just 9% upside.

The real intrigue? Insiders are piling in with over $9.7 million in buys—CEO, directors loading up at dips—bucking Wall Street’s yawn and signaling conviction in a 2026 FCF surge to $2.06/share and revenue rebound. Is this beaten-down value play primed for resurrection via semis/biopharma tailwinds and M&A, or a trap in a commoditizing market? Dive into the full analysis for the risks, catalysts, and contrarian verdict.

Read full commentary →

Avantor, Inc. (AVTR) Latest News

News by impact score

Fine-tune

18 Sep

3 , 9:29 AM
Avantor expands RIM single-use bioprocessing capabilities across APAC markets. APAC bioprocessing expansion supports regional growth but remains limited in scope for overall company trajectory.

25 Aug

3 , 11:43 AM
Avantor, Inc. (AVTR) shows revival progress but continues to face persistent margin pressure, prompting questions about its attractiveness as a buy. Persistent margin pressure amid revival progress may limit Avantor's financial performance improvements and affect investor sentiment.

7 Aug

4 transcript www.fool.com, 8:35 PM
Avantor Inc. (AVTR) releases transcript of its Q2 2026 earnings call covering financial results, performance metrics, and executive outlook. Earnings call content and guidance directly shape near-term stock movement and investor views on operations.

31 Jul

4 , 9:07 PM
Avantor raised 2026 guidance on stronger VWR organic growth, sending shares up 20.5%. Guidance increase points to improved growth outlook that can shift company trajectory and investor views.

30 Jul

4 , 5:01 PM
Avantor Q2 results showed strategic initiatives and segment execution driving an upward revision in company guidance. Upward guidance revision tied to strategic initiatives signals major positive shift in performance outlook.

4 , 12:46 PM
Avantor beat Q2 earnings estimates on VWR growth and raised full-year guidance. Earnings beat plus raised guidance signals stronger performance and outlook that typically moves the stock and sentiment materially.

3 www.trefis.com, 2:29 PM
Avantor shares rose after one business segment stopped contracting. Segment stabilization can lift financial results and share price.

29 Jul

4 www.marketbeat.com, 3:04 PM
Avantor reported Q2 results with revenue and profit figures plus updated guidance and operational updates during its earnings call. Q2 earnings figures and guidance directly influence AVTR valuation and near-term trading.

3 transcript app.moby.co, 4:46 PM
Avantor, Inc. released its Q2 2026 earnings call summary covering financial results, guidance, and operational updates. Quarterly earnings and guidance typically produce moderate short-term effects on stock price and sentiment.

3 , 3:02 PM
Avantor Inc (AVTR) Q2 2026 earnings call highlighted strategic growth initiatives alongside sustained financial resilience and operational stability. Earnings highlights on growth plans and resilience signal moderately noticeable influence on AVTR financial trajectory and sentiment.

3 , 9:30 AM
Avantor (AVTR) Q2 earnings key metrics compared to Wall Street estimates. Q2 earnings metrics versus estimates can influence investor views on Avantor's performance.

3 , 6:45 AM
Avantor reported strong Q2 CY2026 results, driving a sharp rise in its stock price. Strong quarterly results typically lift near-term sentiment without altering long-term fundamentals.

3 , 6:05 AM
Avantor, Inc. released its second quarter 2026 financial results. Quarterly results release key metrics that shape near-term investor views on performance.

22 Jul

3 , 10:00 AM
Avantor, Inc. (AVTR) is projected to surpass upcoming earnings estimates, prompting questions on whether the stock price will rise in response. Earnings estimate beats create moderate short-term stock movement without altering long-term company fundamentals.

15 Jul

3 , 9:01 AM
NuSil expands HIV prevention partnership, driving Avantor stock higher. NuSil partnership expansion offers moderate positive effect on operations without altering long-term trajectory.

14 Jul

3 , 8:05 AM
Avantor's NuSil brand expands partnership with the Population Council to develop long-acting HIV prevention product. Partnership expansion aids specialized product development in HIV prevention with moderate growth implications.

13 Jul

3 , 10:29 AM
Avantor (AVTR) gains traction under new management. New management drives positive traction at Avantor.

29 May

3 Zacks, 11:30 AM
Avantor (AVTR) shares rose 13% since the latest earnings report on positive market reaction to results. Post-earnings stock gains reflect moderate influence on near-term sentiment and valuation.

22 May

3 StockStory, 12:12 AM
Avantor posted Q1 earnings with revenue of $1.79 billion and adjusted EPS of $0.29, both missing consensus estimates. Management lowered full-year organic growth guidance to 1-3% citing weak biopharma demand and inventory destocking. Shares dropped over 4% in after-hours trading as investors weigh recovery timing and margin pressure. Lowered guidance and earnings miss introduce moderate short-term pressure on valuation and sentiment but do not signal structural change in core markets.

18 May

3 Insider Monkey, 9:17 AM
Avantor shares declined after destocking extended longer than expected, pressuring near-term sales and operations. Extended destocking points to sustained demand weakness that can weigh on Avantor's financial results and stock trajectory.

3 Insider Monkey, 9:09 AM
Avantor (AVTR) shares declined after the company issued guidance below market expectations. Lower guidance directly pressures near-term revenue and earnings forecasts.

15 May

3 MT Newswires, 11:36 AM
RBC Capital Markets reports Avantor's turnaround story continues amid ongoing execution risks. RBC's view of ongoing turnaround balanced by execution risks suggests moderately noticeable impact on AVTR's financial performance and sentiment.

3 May

3 Simply Wall St., 9:07 AM
Avantor (AVTR) narrative shifts after valuation reset and execution concerns, prompting reevaluation of its growth story amid operational challenges and market repricing. Valuation reset and execution concerns moderately influence AVTR's investor sentiment and financial trajectory without fundamental redefinition.

30 Apr

3 Insider Monkey, 5:41 PM
William Blair maintains Market Perform rating on Avantor (AVTR) despite CFO departure. CFO departure introduces leadership uncertainty potentially affecting financial oversight, but unchanged analyst rating indicates limited overall trajectory shift.

3 Zacks, 12:36 PM
Avantor Inc. (AVTR) reported Q1 earnings and revenues that beat analyst estimates, though margins declined. Earnings and revenue beats signal solid performance but declining margins temper long-term optimism.

29 Apr

4 www.marketbeat.com, 11:40 PM
Avantor Inc. (AVTR) Q1 earnings call highlights key financial results, operational updates, and forward guidance. Q1 earnings highlights directly impact financial performance, investor sentiment, and stock trajectory through reported results and guidance.

4 transcript www.fool.com, 1:43 PM
Avantor, Inc. (AVTR) released the transcript of its Q1 2026 earnings call, detailing first-quarter financial results, operational performance, and forward-looking guidance. Q1 2026 earnings transcript discloses financial outcomes, management insights, and guidance that could substantially shift AVTR's trajectory and investor sentiment.

4 app.moby.co, 12:50 PM
Avantor, Inc. released Q1 2026 earnings call summary highlighting financial results, operational updates, and outlook. Quarterly earnings summaries detail revenue, guidance, and strategy, significantly impacting AVTR's future performance and investor sentiment.

4 investorshub.advfn.com, 8:54 AM
Avantor Inc. (AVTR) shares surged 9% after first-quarter earnings beat expectations. Q1 earnings beat caused 9% share jump, signaling strong financial health and boosting investor sentiment.

4 Zacks, 7:45 AM
Avantor, Inc. (AVTR) reported Q1 earnings and revenues that exceeded analyst estimates. Exceeding Q1 earnings and revenue estimates boosts investor sentiment and signals strong financial performance.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us